VERAXA Biotech (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG have announced initial positive results from their strategic research collaboration aimed at developing next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and chronic immune diseases. The companies reported that in early in vitro studies, an AOC candidate combining their respective technologies demonstrated greater potency than the equivalent unconjugated oligonucleotide, supporting the potential of this approach to selectively deliver therapeutic oligonucleotides to disease-specific cells.
The collaboration leverages VERAXA's proprietary click chemistry-powered conjugation technology, which the company notes has potential applications beyond its primary focus on solid tumors. Secarna's expertise in antisense oligonucleotide discovery and development complements VERAXA's antibody engineering capabilities, creating a synergistic approach to targeting diseases with high unmet medical need.
"We are encouraged by these early results, which validate the feasibility of our AOC platform to enhance the potency of oligonucleotide therapeutics," said a spokesperson for VERAXA. "The ability to selectively deliver these agents to disease-relevant cells could significantly improve efficacy and reduce off-target effects, potentially transforming treatment paradigms for chronic immune conditions."
The companies are currently discussing next steps in the collaboration, including further preclinical development and potential expansion into additional therapeutic areas. This progress underscores the versatility of VERAXA's conjugation technology, which was originally developed for antibody-drug conjugates (ADCs) but is now showing promise in the emerging field of AOCs.
VERAXA, founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), is focused on building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company's pipeline is advancing rapidly, guided by rigorous quality-by-design principles.
Secarna Pharmaceuticals is a privately held biopharmaceutical company specializing in the discovery and development of antisense oligonucleotide therapies. The company's proprietary platform enables the rapid identification of potent and specific antisense oligonucleotides for a wide range of diseases.
The positive early results from this collaboration highlight the growing interest in AOCs as a novel modality for treating diseases beyond oncology. By combining the targeting capabilities of antibodies with the gene-regulating potential of oligonucleotides, AOCs offer a promising strategy for addressing the underlying drivers of autoimmune and chronic inflammatory conditions.
For more information on VERAXA Biotech, visit the company's newsroom at http://ibn.fm/VRXA.
